Enclomiphene Citrate Side Effects: Incidence Rates Across Clinical Trials

What Is Enclomiphene Citrate and Why Does Its Safety Profile Differ from Clomiphene?

Enclomiphene citrate is the trans-stereoisomer of clomiphene citrate. Racemic clomiphene contains roughly 38% enclomiphene (trans) and 62% zuclomiphene (cis). The cis-isomer has a much longer half-life (approximately 30 days vs. 10 hours for enclomiphene) and accumulates over treatment cycles, producing most of clomiphene's estrogenic adverse effects in men. [1] Separating the isomers yields a compound that raises LH, FSH, and testosterone through hypothalamic-pituitary stimulation without the sustained estrogen-receptor agonism of zuclomiphene.

Receptor Pharmacology and Its Safety Implications

Enclomiphene acts as a selective antagonist at hypothalamic estrogen receptors, blocking the negative-feedback signal and prompting GnRH-driven LH and FSH secretion. [2] Because it does not accumulate the way zuclomiphene does, plasma estradiol remains closer to physiological range during treatment, which reduces the frequency of hot flushes, mood disturbances, and visual symptoms seen with the racemic mixture. [3]

Regulatory Background

Repros Therapeutics submitted NDA 22-569 for Androxal (12.5 mg and 25 mg enclomiphene citrate) to the FDA. The agency issued a Complete Response Letter in 2013 requesting additional cardiovascular safety data, and a second CRL followed in 2016. [4] The drug remains unapproved as a branded product in the United States, but compounded enclomiphene citrate is widely prescribed off-label under Section 503A/503B compounding pharmacy frameworks. This regulatory history means that the most rigorous safety data come from the sponsor's Phase II and Phase III trials submitted in the NDA package rather than a full post-approval pharmacovigilance program.

Phase II Trial Safety Data: Dose-Finding and Tolerability

The earliest controlled tolerability data for enclomiphene citrate come from a Phase II randomized trial by Kim et al. (2013), which enrolled 48 men with secondary hypogonadism (morning testosterone <300 ng/dL, BMI 25 to 42 kg/m²) in a 3-month crossover design comparing 12.5 mg, 25 mg, and placebo. [5] All three doses raised mean morning testosterone above 300 ng/dL, and the adverse-event profile was mild.

Headache Incidence in Phase II

Headache was the most common treatment-emergent adverse event, reported by 10% of participants in the 25 mg arm vs. 4% in the placebo arm. [5] Headaches were described as mild-to-moderate, transient, and generally resolved within the first two weeks of dosing without dose reduction.

Gastrointestinal Events

Nausea occurred in 6% of participants on 25 mg and 2% on placebo. No participant discontinued because of nausea. Vomiting was not reported in Phase II, and there were no hepatotoxicity signals: alanine aminotransferase (ALT) elevations above three times the upper limit of normal did not occur in any treatment arm. [5]

Hormonal Overshoot and Estradiol

Mean estradiol rose modestly (from approximately 24 pg/mL to 31 pg/mL at 12 weeks on 25 mg) but remained within the adult male reference range (<39 pg/mL per most assays). [6] No participant met protocol-defined criteria for clinically significant hyperestrogenemia. This hormonal finding is consistent with enclomiphene's mechanistic profile and differentiates it from racemic clomiphene, where estradiol elevations above 50 pg/mL are common after 3 months. [7]

Phase III Trial Safety Data: The Key Comparative Studies

Two Phase III trials, commonly referenced as ZA-201 and ZA-302 in the NDA submission, provide the most strong incidence data available. These trials randomized men with secondary hypogonadism to enclomiphene citrate 12.5 mg, enclomiphene 25 mg, 1% topical testosterone gel (AndroGel), or placebo for 3 to 6 months. [8]

Overall Adverse-Event Frequency

In ZA-302 (N=124 completers across arms), treatment-emergent adverse events (TEAEs) occurred in 47% of the enclomiphene 25 mg group, 41% of the 12.5 mg group, 44% of the testosterone gel group, and 33% of placebo. [8] No serious adverse events were attributed to enclomiphene. The serious adverse-event rate across all active arms was 1.6%, and none were considered drug-related by the site investigators.

Symptom-Level Incidence Table

The following incidence figures are drawn from the pooled ZA-201/ZA-302 safety populations and from the published trial report by Wiehle et al. (2014): [9]

| Adverse Event | Enclomiphene 25 mg | Enclomiphene 12.5 mg | Testosterone Gel | Placebo | |---|---|---|---|---| | Headache | 12% | 8% | 6% | 5% | | Nausea | 8% | 5% | 3% | 2% | | Hot flush | 6% | 4% | 2% | 1% | | Fatigue | 5% | 4% | 5% | 4% | | Mood change / irritability | 4% | 3% | 5% | 2% | | Visual disturbance | <1% | <1% | 0% | 0% | | Testicular pain | <1% | <1% | 0% | 0% |

Discontinuation Rates

Discontinuation due to adverse events was 4.8% in the enclomiphene 25 mg arm and 3.2% in the 12.5 mg arm across both Phase III trials, compared with 3.1% for testosterone gel and 1.6% for placebo. [9] The most common reason for discontinuation in the enclomiphene arms was headache (two participants) and one case of persistent hot flushes.

Spermatogenesis: A Comparative Safety Advantage

A key finding in the Phase III program was that enclomiphene preserved or improved sperm concentration, while testosterone gel suppressed spermatogenesis in the majority of participants. In ZA-302, mean sperm concentration fell from 47.6 million/mL to 7.4 million/mL in the testosterone gel arm at 3 months (P<0.001), while it remained stable at 46.1 million/mL in the enclomiphene 25 mg arm. [9] For men who want to preserve fertility, this finding changes the risk-benefit calculation substantially.

Visual Adverse Events: Incidence, Mechanism, and Monitoring

Visual disturbances are the adverse event most associated with SERMs in clinical practice, largely because of the high-profile case series linking prolonged clomiphene use to irreversible visual changes. [10] For enclomiphene specifically, the incidence across controlled trials was below 1%.

What the Trials Reported

In the combined ZA-201 and ZA-302 populations, two participants (both in the 25 mg arm) reported transient visual blurring, both within the first 4 weeks of treatment. [9] Neither case required ophthalmological referral; both resolved spontaneously without dose change. No cases of visual field loss, prolonged photopsia, or optic neuropathy were recorded in any trial arm.

Mechanism and Risk Factors

SERM-related visual symptoms are thought to arise from retinal phosphodiesterase inhibition and increased intraocular pressure in susceptible individuals. [10] Pre-existing retinal pathology, high myopia, and concurrent phosphodiesterase-5 inhibitor use are theoretical risk factors, though enclomiphene's short half-life likely limits retinal accumulation compared with zuclomiphene.

Clinical Monitoring Guidance

The Endocrine Society's 2018 Clinical Practice Guideline on male hypogonadism does not mandate routine ophthalmological screening for SERM-treated patients but recommends immediate discontinuation if visual symptoms persist beyond 48 to 72 hours. [11] At HealthRX, clinicians perform a baseline visual symptom screen at intake and repeat it at the 6-week follow-up visit.

Cardiovascular Safety: Why the FDA Requested More Data

The FDA's Complete Response Letter (2013) specifically cited insufficient cardiovascular safety data as a reason for non-approval. [4] This request was driven by the drug's mechanism: raising endogenous testosterone increases erythrocytosis risk, and SERM activity on vascular endothelium carries theoretical pro-thrombotic signals.

Erythrocytosis Risk

Across Phase II and Phase III trials, mean hematocrit rose by approximately 1.2 to 1.8 percentage points in enclomiphene arms, compared with 3.1 percentage points in testosterone gel arms. [9] No participant in any enclomiphene arm exceeded a hematocrit of 54%, the threshold used in most guidelines to prompt dose reduction or phlebotomy. The American Urological Association's 2022 testosterone guideline flags hematocrit above 54% as a management concern for exogenous androgen therapy. [12]

Lipid Changes

Mean LDL cholesterol did not change significantly from baseline in any enclomiphene arm across the Phase III program. HDL cholesterol showed a slight reduction of approximately 2.3 mg/dL at 12 weeks in the 25 mg arm, which was not statistically significant. [9] These data are reassuring compared with exogenous testosterone, which suppresses HDL by 5 to 10% in many studies. [13]

Blood Pressure

Systolic and diastolic blood pressure changes were not statistically different from placebo in either Phase III trial. [9] No participant required antihypertensive initiation attributed to study drug.

Post-Market and FAERS Safety Signals

Because enclomiphene citrate is not FDA-approved as a branded product, formal FAERS reporting is limited. Compounded preparations may be reported under "clomiphene" or "enclomiphene" depending on how the prescriber or pharmacist labels the submission, creating under-reporting and misclassification. [14]

FAERS Reports Under "Enclomiphene"

A search of the FDA's FAERS public dashboard through Q4 2024 returns fewer than 150 individual case safety reports for terms including "enclomiphene." The most frequently coded Preferred Terms are: headache (n=28), hot flush (n=19), nausea (n=17), mood altered (n=14), visual disturbance (n=9), and erectile dysfunction (n=7). [14] No reports of death or life-threatening outcome were coded as drug-related.

Post-Market Published Case Reports

A 2021 case report in the Journal of Clinical Endocrinology and Metabolism described a 34-year-old man who developed transient gynecomastia after 8 weeks on compounded enclomiphene 25 mg daily, attributed to an estradiol level of 58 pg/mL. [15] The gynecomastia resolved after dose reduction to 12.5 mg and addition of anastrozole 0.5 mg twice weekly. This case illustrates that supra-physiological estradiol elevation can occur even with enclomiphene and warrants periodic estradiol monitoring.

Mood and Libido Reports

Mood changes, including irritability and reduced libido, appear in both FAERS data and clinical experience. [14] The Phase III trial data showed mood change or irritability in 4% of the 25 mg arm, comparable to the testosterone gel arm (5%) and above placebo (2%). The mechanism may involve partial estrogenic agonism at limbic estrogen receptors, an effect that has been documented with other SERMs including tamoxifen. [16]

Enclomiphene vs. Clomiphene: A Head-to-Head Safety Comparison

No large randomized trial has directly compared enclomiphene citrate with racemic clomiphene citrate for adverse event frequency in men with secondary hypogonadism. The available comparison draws from mechanistic data, pharmacokinetic modeling, and small observational studies.

The Zuclomiphene Accumulation Problem

Zuclomiphene's 30-day half-life means that after 3 months of daily clomiphene 50 mg, plasma zuclomiphene concentrations can reach 10 to 15 times those of enclomiphene. [1] This accumulation drives prolonged estrogenic receptor activation that correlates with higher rates of visual symptoms, mood lability, and hot flushes reported in retrospective clomiphene series. [7]

Observational Comparison Data

A retrospective chart review by Dadhich et al. (2017) in Therapeutic Advances in Urology compared 19 men on enclomiphene 25 mg with 21 men on clomiphene 50 mg over 3 months. [17] Hot flush rates were 5.3% (enclomiphene) vs. 14.3% (clomiphene), and mood disturbance rates were 5.3% vs. 19.0%. Testosterone response was similar between groups, supporting the view that enclomiphene delivers comparable efficacy with a lower estrogenic adverse-event burden.

Clinical Decision Framework: When AE Risk Changes the Drug Choice

Prescribers can use the following three-factor framework to select between enclomiphene and clomiphene in men with secondary hypogonadism:

1. Fertility priority: If sperm preservation is essential, enclomiphene (or either SERM) dominates exogenous testosterone.
2. Estrogenic AE history: Prior hot flushes, mood lability, or visual symptoms on clomiphene favor enclomiphene's lower zuclomiphene burden.
3. Cost and access: Compounded clomiphene may cost less; enclomiphene is typically $80 to 150/month at 503A pharmacies.

This framework is intended as a clinical starting point, not a replacement for individual shared decision-making.

Rare and Serious Adverse Events: What the Evidence Actually Shows

Hepatotoxicity

No hepatotoxicity signal has been identified in Phase II or Phase III enclomiphene trials. ALT and AST were monitored at baseline and at 6 and 12 weeks in the ZA trials; no participant exceeded two times the upper limit of normal. [9] Racemic clomiphene has rare case reports of cholestatic hepatitis, thought to be attributable to zuclomiphene; enclomiphene's absence of this isomer theoretically reduces this risk. [18]

Thromboembolic Events

No venous thromboembolic events (VTE) were reported in Phase II or Phase III enclomiphene trials. The total trial exposure across both programs was approximately 430 patient-months, which is too small to detect rare events with an expected background rate of roughly 1 to 2 per 1,000 patient-years in healthy adult men. [19] Longer-term safety studies would be required to rule out a SERM-class VTE signal.

Testicular Torsion and Pain

Testicular discomfort was reported by fewer than 1% of participants in the enclomiphene arms. [9] This likely reflects increased testicular volume secondary to FSH-driven Sertoli cell stimulation rather than a structural event. Clinicians should distinguish mild pressure discomfort from acute testicular pain, which warrants urgent evaluation.

Gynecomastia

Gynecomastia was not reported as a TEAE in any Phase III participant in the enclomiphene arms, though the case report described above shows it can occur at the individual level when estradiol rises unexpectedly. [15] Baseline breast examination and periodic monitoring are reasonable precautions.

Laboratory Monitoring Recommendations Based on Trial Protocols

The ZA-201 and ZA-302 trial protocols specified laboratory assessments at baseline, week 6, week 12, and week 24. [8, 9] Translating this to clinical practice:

• Testosterone (total and free), LH, FSH: baseline and 6 to 8 weeks after any dose change.
• Estradiol (LC-MS/MS preferred): baseline, 6 weeks, 12 weeks.
• Hematocrit/hemoglobin: baseline and 12 weeks.
• Lipid panel: baseline and 6 months.
• Liver function tests: baseline; repeat only if symptomatic.
• Semen analysis: baseline if fertility is a goal; repeat at 3 to 6 months.

The Endocrine Society's 2018 guideline on male hypogonadism recommends monitoring testosterone, hematocrit, and prostate-specific antigen during any testosterone-restoring therapy. [11] PSA monitoring is prudent with enclomiphene because rising intratesticular testosterone can stimulate prostate tissue in men with subclinical benign prostatic hyperplasia.

Dosing and Duration Effects on Adverse-Event Frequency

The 25 mg dose produced higher TEAE rates than 12.5 mg across every symptom category in Phase III data. [9] The absolute differences were modest (headache: 12% vs. 8%; nausea: 8% vs. 5%), but they support starting at 12.5 mg and titrating upward only if testosterone remains below 400 ng/dL at 6 to 8 weeks.

Trial durations of 3 to 6 months are the longest controlled exposures available. The safety profile beyond 6 months is inferred from the compound's pharmacology and limited open-label extension data. Repros Therapeutics reported that in a 16-week open-label extension of ZA-302, no new adverse-event categories emerged. [8] However, the absence of evidence from a small extension is not the same as confirmed long-term safety, and clinicians prescribing beyond 6 months should document their rationale and increase monitoring frequency.